▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2685 by analyst upside · 2026-09-27
PTGX
Protagonist Therapeutics, Inc.
Healthcare · Market Cap $9B · P/E 136.4x
ANALYST PRICE TARGET
+23.1%
implied upside to consensus target
Current Price $141.86
Consensus Target $174.69
Bull Target $225.0
Bear Target $149.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
0
Sell
0
52-Week Low $62.24
52-Week High $160.81
YTD Return +62.7%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) 136.4x
Forward P/E N/A
EPS (TTM) $1.04
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $282M
Profit Margin 29.4%
52-WEEK RANGE
52-Week Low $62.24
52-Week High $160.81
Current Price $141.86
Bear Target $149.0
Bull Target $225.0
● Now $141.86 ● Target $174.69
TRADING DATA
Avg Volume 620K
YTD Return +62.7%
Analyst Count 13
Consensus Buy
Upside to Target +23.1%
Last Updated 2026-09-27

ANALYST SUMMARY

Protagonist Therapeutics, Inc. (PTGX) is currently trading at $141.86 with a Wall Street consensus price target of $174.69, implying potential upside of 23.1% over the next 12 months. 13 analysts currently cover PTGX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $225.0, while the most cautious has a target of $149.0.

PTGX operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 62.7% year-to-date and is currently trading near the upper end of its 52-week range of $62.24 – $160.81.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PTGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-09-01 Building track record
BMO Capital - Reiterated
Outperform → Outperform 2026-09-01 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-31 31% win rate (48 calls)
BMO Capital - Reiterated
Outperform → Outperform 2026-08-17 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-10 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-08-10 Building track record
Goldman Sachs ↑ Upgrade
Neutral → Buy 2026-08-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
20/30
Consensus clarity
19/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →